aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Simcha Therapeutics, founded with a mission to advance new medicines that bring hope to cancer patients, focuses on engineering novel cytokines through directed evolution. The company aims to harness the precision and power of the immune system to develop transformational immunotherapies. By leveraging cutting-edge science, Simcha Therapeutics is dedicated to creating next-generation drugs that can significantly impact patient outcomes in the oncology market.
Notable figures affiliated with Simcha Therapeutics include a distinguished leadership team and a board of directors with extensive experience in biotechnology and drug development. The company has attracted significant investment from leading venture capital firms in the life sciences sector. Key achievements include the development of a robust pipeline of innovative therapies and recognition within the scientific community for their pioneering approach. Simcha Therapeutics is making a substantial impact by pushing the boundaries of immunotherapy and offering new hope to cancer patients worldwide.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Immunotherapies
Technology
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Simcha Therapeutics founded?
Simcha Therapeutics was founded in 2018.
Where is Simcha Therapeutics's headquarters located?
Simcha Therapeutics's headquarters is located in New Haven, CT, US.
When was Simcha Therapeutics's last funding round?
Simcha Therapeutics's most recent funding round was for $40M (USD) in January 2022.
How many employees does Simcha Therapeutics have?
Simcha Therapeutics has 13 employees as of Feb 4, 2024.
How much has Simcha Therapeutics raised to-date?
As of July 05, 2023, Simcha Therapeutics has raised a total of $65M (USD) since Jan 27, 2022.
Add Comparison
Total Raised to Date
$65M
USD
Last Update Jan 27, 2022
Last Deal Details
$40M
USD
Jan 27, 2022
Series B
Total Employees Over Time
13
As of Feb 2024
Simcha Therapeutics Address
New Haven,
Connecticut
06510
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts